Full Text View
Tabular View
Study Results
Related Studies
Fasted Bioavailability Study of Cilostazol Tablets, 50mg
This study has been completed.
Study NCT00685802   Information provided by Mutual Pharmaceutical Company, Inc.

First Received on May 24, 2008.   Last Updated on November 18, 2009   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Therapeutic Equivalency, Healthy
Interventions listed in this trial
Cilostazol 50 mg Tablets
Cilostazol (Pletal®) 50 mg Tablets
Additional drug interventions recognized in this trial
Cilostazol
More general drug interventions related to this trial
Anti-Asthmatic Agents
Autonomic Agents
Bronchodilator Agents
Cardiovascular Agents
Central Nervous System Agents
Enzyme Inhibitors
Fibrin Modulating Agents
Fibrinolytic Agents
Hematologic Agents
Molecular Mechanisms of Pharmacological Action
Neuroprotective Agents
Peripheral Nervous System Agents
Pharmacologic Actions
Phosphodiesterase 3 Inhibitors
Phosphodiesterase Inhibitors
Physiological Effects of Drugs
Platelet Aggregation Inhibitors
Protective Agents
Respiratory System Agents
Therapeutic Uses
Vasodilator Agents
Sponsors listed in this trial
Mutual Pharmaceutical Company, Inc.


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services